U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07550517) titled 'PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT' on April 07.
Brief Summary: This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6 months) is (1) safe and effective compared to standard of care alone, and (2) can reduce the side effects caused by long-term (24 months) ADT in men with high risk localized prostate cancer.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
High-Risk Localized Prostate Cancer
Intervention:
DRUG: EBRT + 6 mo ADT ...